AstraZeneca's respiratory tract infection treatment gets prior status from European Medicines Agency

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 07:52

AstraZeneca said Tuesday its treatment for lower respiratory tract infection caused by the respiratory syncytial virus had received priority status from the European Medicines Agency.

The PRIME (PRIority MEdicines) initiative offered proactive and enhanced support to developers of promising medicines to optimise development plans and accelerate evaluation so these medicines can reach patients faster.

This was the first EMA PRIME eligibility that AstraZeneca had received since the programme's initiation in 2016.

'We are excited to receive PRIME eligibility for MEDI8897, our next-generation monoclonal antibody targeting respiratory syncytial virus in infants. We will work closely with the European Medicines Agency to optimise our development plan and help us bring MEDI8897 to patients as quickly as possible,' said Mene Pangalos, Executive Vice-President, R&D BioPharmaceuticals.

Related content

Using ETFs to invest in quality companies


You can use exchange-traded funds (ETFs) to access many different types of shares, grouped according to whatever criteria you like. For example, you can use...

Thu, 19/09/2019 - 00:00

AstraZeneca amends collaboration with Ironwood

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China mainland, China Hong Kong, and China Macau for Linzess.

This new agreement gives AstraZeneca...

Wed, 18/09/2019 - 07:16

Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8200p (from 8000p).

Broker Forecasts data provided...

Fri, 13/09/2019 - 10:10

Time to take profit in AstraZeneca


AstraZeneca (AZN) £68.57

Gain to date: 8.9%

Original entry price: Buy at £63.00, 15 November 2018

Our positive...

Thu, 12/09/2019 - 00:00

British stocks ripe for a foreign takeover


Last year was a vintage one for mergers and acquisitions (M&A) with deals totalling more than $4trn, the highest figure since 2007 and the onset...

Thu, 12/09/2019 - 00:00